BioSpace News Archive

Daewoong Pharmaceutical, a global pharmaceutical company located in Seoul, announced its marvelous financial results for 2023.

In a groundbreaking development for brain tumor care in Poland, the Neurosurgery Centre at N. Copernicus Hospital in Gdansk is thrilled to announce the imminent installation of the ZAP-X® Gyroscopic Radiosurgery® platform.

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that it will present at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually on Tuesday, February 13, 2024, at 9:20 a.m. ET.

BostonGene announced today that it will participate in and present at the SLAS2024 International Conference and Exhibition on February 3 - 7, 2024, in Boston, MA.

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually from February 13-14, 2024.

Aprea Therapeutics, Inc. today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to initiate clinical trials of APR-1051.

Ovid Therapeutics Inc. today announced that management will participate in a virtual presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m. ET.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its second review of trial data and recommended the ATH434-201 Phase 2 study continue as planned.

Trevi Therapeutics, Inc. today announced that Jennifer Good, President and Chief Executive Officer, will be presenting at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, at 10:00 a.m. ET.

Golden State Medical Supply, a leading provider of generic pharmaceuticals to the US Federal Government and Finarb Analytics Consulting, a consult-to-operate data and AI solutions provider, have announced a strategic partnership to develop an AI enabled demand forecasting model to accurately estimate demand across all client facilities of GSMS.